Non-small-cell lung cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature Reviews Disease Primers

• Publication date

  2015-05-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrdp.2015.9PMID 27188576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2017cited by this paper
• Summary of Published Evidence

  2017cited by this paper
• Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

  2016cited by this paper
• The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2015cited by this paper
• Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study.

  2015cited by this paper
• Curcumin and resveratrol in combination modulate drug-metabolizing enzymes as well as antioxidant indices during lung carcinogenesis in mice

  2015cited by this paper
• The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

  2014cited by this paper
• Oncogenic RIT1 mutations in lung adenocarcinoma

  2014cited by this paper
• Comprehensive molecular profiling of lung adenocarcinoma

  2014cited by this paper
• Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.

  2014cited by this paper
• An era of lung cancer iconoclasts.

  2014cited by this paper
• Germline EGFR T790M mutation found in multiple members of a familial cohort.

  2014cited by this paper
• TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers

  2014cited by this paper
• Overdiagnosis in low-dose computed tomography screening for lung cancer.

  2014cited by this paper
• Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.

  2014cited by this paper
• Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).

  2014cited by this paper
• LBA2_PRGEFITINIB/CHEMOTHERAPY VS CHEMOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) AFTER PROGRESSION ON FIRST-LINE GEFITINIB: THE PHASE III, RANDOMISED IMPRESS STUDY

  2014cited by this paper
• Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

  2014cited by this paper
• Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer

  2014cited by this paper
• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity

  2014cited by this paper
• Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement

  2014cited by this paper
• ESTS textbook of thoracic surgery

  2014cited by this paper
• Emerging drugs targeting PD-1 and PD-L1: reality or hope?

  2014cited by this paper
• Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

  2014cited by this paper
• SYK is a critical regulator of FLT3 in acute myeloid leukemia.

  2014cited by this paper
• Cancer: Clonal cooperation

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

  2014cited by this paper
• Attack of the clones

  2014cited by this paper
• Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.

  2014cited by this paper
• Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

  2014cited by this paper
• Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study

  2014cited by this paper
• Lung cancer screening with low-dose CT (LDCT), or when a public health intervention is beyond the patient’s benefit

  2014cited by this paper
• 1223OASPIRATION: FIRST-LINE ERLOTINIB (E) UNTIL AND BEYOND RECIST PROGRESSION (PD) IN ASIAN PATIENTS (PTS) WITH EGFR MUTATION-POSITIVE (MUT+) NSCLC.

  2014cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.

  2014cited by this paper
• Effect of chemotherapy on quality of life in patients with non-small cell lung cancer

  2014cited by this paper
• Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

  2014cited by this paper
• Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging.

  2014cited by this paper
• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

  2014cited by this paper
• Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

  2014cited by this paper
• Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.

  2014cited by this paper
• Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.

  2014cited by this paper
• Ibrutinib treatment of CLL: the cancer fights back.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• Third-generation EGFR-TKIs—a new hope for NSCLC.

  2014cited by this paper
• Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

  2014cited by this paper
• Epidemiology: The dominant malignancy

  2014cited by this paper
• Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

  2013cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013cited by this paper
• Genetics and biomarkers in personalisation of lung cancer treatment.

  2013cited by this paper
• Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cited by this paper
• Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

  2013cited by this paper
• Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas

  2013cited by this paper
• Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

  2013cited by this paper
• Molecular sputum analysis for the diagnosis of lung cancer

  2013cited by this paper
• Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cited by this paper
• ALK in lung cancer: past, present, and future.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE).

  2013cited by this paper
• New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

  2013cited by this paper
• Noncovalent wild-type-sparing inhibitors of EGFR T790M.

  2013cited by this paper
• Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer

  2013cited by this paper
• Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

  2013cited by this paper
• Acquired resistance to crizotinib from a mutation in CD74-ROS1.

  2013cited by this paper
• 'Cancer associated fibroblasts'--more than meets the eye.

  2013cited by this paper
• Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

  2013cited by this paper
• Tecemotide ( L-BLP 25 ) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer ( START ) : a randomised , double-blind , phase 3 trial

  2013cited by this paper
• Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

  2013cited by this paper
• Case 16-2013: A girl with irritability, hypersomnia, and somatic symptoms.

  2013cited by this paper
• Case 16-2013: A girl with irritability, hypersomnia, and somatic symptoms.

  2013cited by this paper
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

  2013cited by this paper
• LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations.

  2013cited by this paper
• An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

  2013cited by this paper
• The quest to overcome resistance to EGFR-targeted therapies in cancer

  2013cited by this paper
• PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

  2013cited by this paper
• Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss

  2013cited by this paper
• Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

  2012cited by this paper
• Lung cancer in never smokers--a review.

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium.

  2012cited by this paper
• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

  2012cited by this paper
• Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands.

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

  2012cited by this paper
• Comprehensive genomic characterization of squamous cell lung cancers

  2012cited by this paper
• Systematic Reviews and Meta-and Pooled Analyses Previous Lung Diseases and Lung Cancer Risk : A Pooled Analysis From the International Lung Cancer Consortium

  2012cited by this paper
• Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

  2012cited by this paper
• Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

  2012cited by this paper
• Genetic insight and therapeutic targets in squamous-cell lung cancer

  2012cited by this paper
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

  2012cited by this paper

• Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.

  2026cites this paper
• An inhalable liquid-core lipid nanoplatform enables macrophage-mediated mRNA delivery to lung tumors.

  2026cites this paper
• Transmembrane proteome analysis of frozen mouse lung tissues by LC-MS using metal organic framework-based protein extraction.

  2026cites this paper
• miR-320a enhances radiosensitivity in non-small cell lung cancer by targeting RAD51 and modulating ferroptosis via GPX4.

  2026cites this paper
• Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non‐Small Cell Lung Cancer With ROS1 Rearrangement

  2026cites this paper
• Evolving Patterns of Care, Outcomes and Ongoing Challenges for Early‐Stage Non‐Small Cell Lung Cancer in the Immunotherapy Era: A Queensland Population‐Based Study

  2026cites this paper
• Differences in the expression profiles of m6A-related genes and the prognostic role in immunotherapy for lung adenocarcinoma patients

  2026cites this paper
• Molecular Docking and MD Modeling Techniques for the Development of Novel ROS1 Kinase Inhibitors.

  2026cites this paper
• Habitat-Based Radiomics on Dual-Energy CT for Preoperative Assessment of Invasiveness in Lung Adenocarcinoma with Ground-Glass Nodules.

  2026cites this paper
• Quercetin Nanoemulsion Ameliorates Key Hallmarks of Lung Cancer

  2026cites this paper
• Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.

  2026cites this paper
• Ex-PALM: a negative pressure ventilation system for air leak evaluation in ex vivo lungs

  2026cites this paper
• ICIsc: A Deep Learning Framework for Predicting Immune Checkpoint Inhibitor Response by Integrating scRNA-Seq and Protein Language Models.

  2026cites this paper
• Imidazole-[1,5‑a]‑Pyridines Can Occupy the EGFR Allostery with a Strong Polar Interaction.

  2026cites this paper
• Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China

  2026cites this paper
• Development and Validation of a Frailty Risk Prediction Model for Preoperative Non-Small-Cell Lung Cancer Patients: A Cross-Sectional Study.

  2026cites this paper
• Decision conflict, psychological resilience, and financial toxicity in early-stage non-small-cell lung cancer in China: A latent profile and mediation analysis

  2026cites this paper
• First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

  2026cites this paper
• Identification of exosome-related genes in NSCLC via integrated bioinformatics and machine learning analysis

  2025cites this paper
• Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second‐Line Treatment of Advanced Non–Small Cell Lung Cancer

  2025cites this paper
• The updated network meta-analysis of the therapeutic efficacies of lung cancer: A systematic review and meta-analysis

  2025cites this paper
• Unraveling the role of HDAC3 as an immunotherapy prognostic biomarker and therapeutic target in advanced non-small cell lung cancer

  2025cites this paper
• DNMT3A triggers tumorigenesis of non-small cell lung cancer through regulation of SLIT2 methylation and SLIT2-mediated macrophage M1/M2 polarization.

  2025cites this paper
• Dauricine Impedes the Tumorigenesis of Lung Adenocarcinoma by Regulating Nrf2 and Reactive Oxygen Species

  2025cites this paper
• PGC-1α Promotes NSCLC Progression via FOXM1 Interaction and MUC1 Upregulation

  2025cites this paper
• A Neovascularization and EGFR Dual‐Targeting Gold Nanotheranostic System for Non‐Small Cell Lung Cancer Treatment

  2025cites this paper
• Anti-Programmed Cell Death-1 Versus Anti-Programmed Death-Ligand 1 (PD-L1) in PD-L1-Negative Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2025cites this paper
• Palbociclib- and regorafenib-loaded nanomicelles for the treatment of non-small cell lung cancer: pharmacokinetic and antitumor evaluations

  2025cites this paper
• Remodeling the Tumor Microenvironment via Metal-Phenolic Network-Coated Poly(lactic acid-co-glycolic acid) Nanoparticles for Inducing Multimodal Combination Therapy in Non-Small Cell Lung Cancer.

  2025cites this paper
• Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells

  2025cites this paper
• Calcium triggers calmodulin degradation to induce EGF receptor instability and overcome non-small cell lung cancer resistance to tyrosine kinase inhibitors

  2025cites this paper
• Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions

  2025cites this paper
• Lung Cancer Organoids in Translational Research: Bridging Basic Science, Drug Development, and Clinical Therapeutics.

  2025cites this paper
• Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy

  2025cites this paper
• CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549

  2025cites this paper
• Arjunolic acid from Rhodomyrtus tomentosa Suppresses Growth of Non-Small Cell Lung Cancer via Inducing Autophagy and Apoptosis

  2025cites this paper
• A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer.

  2025cites this paper
• Hsa_circ_0006006 is a potential biomarker for prognosis and cisplatin resistance in non-small cell lung cancer

  2025cites this paper
• Targeting MAPK Signaling: Loureirins A and B from Dracaena Loureiri Inhibit Epithelial–Mesenchymal Transition and Invasion in Non-Small Cell Lung Cancer Cell Lines

  2025cites this paper
• Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.

  2025cites this paper
• Maneuvering the Bioactivities using Functionalized Biginelli Dihydropyrimidinone Amine Derivatives: Zebrafish Model System Tagged Biotoxicity is No Longer 'Fishy'

  2025cites this paper
• ADH1B regulates tumor stemness by activating the cAMP/PKA/CREB1 signaling axis to inhibit recurrence and metastasis of lung adenocarcinoma.

  2025cites this paper
• An Agrin–YAP/TAZ Rigidity Sensing Module Drives EGFR‐Addicted Lung Tumorigenesis

  2025cites this paper
• Construction of a circRNA-miRNA-mRNA Regulatory Network for the Immune Regulation of Lung Adenocarcinoma

  2025cites this paper
• Single-Cell eQTL Mapping Reveals Cell Type-Specific Genetic Regulation in Lung Cancer

  2025cites this paper
• Acute Interstitial Pneumonia Caused by Dual-Target Therapy in Resistant EGFR-Mutated Lung Adenocarcinoma: A Case Report and Literature Review

  2025cites this paper
• Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection

  2025cites this paper
• The potential of secretogranin V as a prognostic biomarker in non-small cell lung cancer

  2025cites this paper
• Mapping the Lung-Brain Axis: Causal Relationships Between Brain Network Connectivity and Respiratory Disorders.

  2025cites this paper
• Surgery Versus Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer (NSCLC): A Comprehensive Review of Survival and Local Control Outcomes

  2025cites this paper
• Immunological biomarkers and gene signatures predictive of radiotherapy resistance in non-small cell lung cancer

  2025cites this paper
• Multi-omics unveils BCAA metabolism markers L-leucine and HMGCS1 as prognostic marker for immunotherapy efficacy in non-small cell lung cancer

  2025cites this paper
• Identification of therapeutic targets in lung adenocarcinoma using Mendelian randomization and multi-omics

  2025cites this paper
• Exploring AI tools and multi-omics for precision medicine in lung cancer therapy.

  2025cites this paper
• Advances in molecular pathology and therapy of non-small cell lung cancer

  2025cites this paper
• Prediction of lung adenocarcinoma prognosis and clinical treatment efficacy by telomere-associated gene risk model

  2025cites this paper
• Accurate prediction of disease-free and overall survival in non-small cell lung cancer using patient-level multimodal weakly supervised learning

  2025cites this paper
• Influence of migrasome-associated long noncoding RNAs on the immune microenvironment and prognosis in lung adenocarcinoma

  2025cites this paper
• Association Between Metformin Use and Mortality Among Individuals With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study.

  2025cites this paper
• Nanodrug Modulates Premetastatic Niche and Suppresses Metastatic Lung Adenocarcinoma via Programmed Cell Death Ligand 1 Blockade and STING Pathway Activation.

  2025cites this paper
• Hybrid Approaches for Identification of Lung Cancer Using Image Processing

  2025cites this paper
• Co‐Encapsulated Niosomes With Metformin and Silver Nanoparticles as Potential Anticancer Tool for the Combined Therapy on Lung Cancer Cells

  2025cites this paper
• PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)

  2025cites this paper
• Combination of growth hormone receptor antagonist and radiation reduces tumour growth in a lung cancer xenograft model.

  2025cites this paper
• Resolving the spatial and cellular architecture of intra-tumor heterogeneity by multi-region dissection of lung adenocarcinoma.

  2025cites this paper
• Development and validation of a transcription factor regulatory network‐based signature for individualized prognostic risk in lung adenocarcinoma

  2025cites this paper
• Robust prognostic biomarkers and a risk prediction model specific to EGFR-mutated lung adenocarcinoma patients via multicohort meta-analysis

  2025cites this paper
• COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma

  2025cites this paper
• A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer

  2025cites this paper
• Single-Cell Sequencing Reveals the Role of Radiation-Induced Stemness-Responsive Cancer Cells in the Development of Radioresistance

  2025cites this paper
• Fear of cancer recurrence in patients with early-stage non-small cell lung cancer: A latent profile analysis

  2025cites this paper
• Hybrid Approach to Classifying Histological Subtypes of Non-small Cell Lung Cancer (NSCLC): Combining Radiomics and Deep Learning Features from CT Images

  2025cites this paper
• Patient and caregiver insights into lung cancer treatment decision-making: an exploratory focus group

  2025cites this paper
• Mitochondrial carrier homolog 2 is important for mitochondrial functionality and non-small cell lung cancer cell growth

  2025cites this paper
• Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study.

  2025cites this paper
• Geniposide Inhibits Non-Small Cell Lung Cancer by Regulating Proliferation, Apoptosis, Invasion, Migration, Epithelial-Mesenchymal Transition, and Cancer Stem-Like Cell Property Via Wnt/β-Catenin Pathway

  2025cites this paper
• Targeting Kinesins for Therapeutic Exploitation of Chromosomal Instability in Lung Cancer

  2025cites this paper
• Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis

  2025cites this paper
• Advances in polymer nanomaterials targeting cGAS-STING pathway for enhanced cancer immunotherapy.

  2025cites this paper
• GATA2 promotes M1 macrophage polarization and inhibits the malignant progression of lung adenocarcinoma through transcription activation-mediated upregulation of KANK3

  2025cites this paper
• The multiple biological activities of hyperoside: from molecular mechanisms to therapeutic perspectives in neoplastic and non-neoplastic diseases

  2025cites this paper
• Panduratin A from Boesenbergia rotunda Effectively Inhibits EGFR/STAT3/Akt Signaling Pathways, Inducing Apoptosis in NSCLC Cells with Wild-Type and T790M Mutations in EGFR

  2025cites this paper
• The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer

  2025cites this paper
• Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression

  2025cites this paper
• Development of a PET-CT Based Radiomics Model for Preoperative Prediction of the Novel IASLC Grading and Prognosis in Patients with Clinical Stage I Pure Solid Invasive Lung Adenocarcinoma.

  2025cites this paper
• Synergistic Strategies for Lung Cancer Immunotherapy: Combining Phytochemicals and Immune‐Checkpoint Inhibitors

  2025cites this paper
• Recent advancement in the anticancer efficacy of the natural flavonoid scutellarin: a comprehensive review

  2025cites this paper
• Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma

  2025cites this paper
• m6A modified SFTA1P acts as a tumor suppressor in non-small cell lung cancer by regulating TGFBR2 and P-TEFb.

  2025cites this paper
• Targeted Cancer Therapy with Gold–Iron Oxide Nanourchins: Inducing Oxidative Stress, Paraptosis, and Sensitizing Tumor Cells to Cisplatin

  2025cites this paper
• Intelligent Point-of-Care Biosensing Platform Based on Luminescent Nanoparticles and Microfluidic Biochip with Machine Vision Algorithm Analysis

  2025cites this paper
• Verteporfin‐Mediated In Situ Nanovaccine Based on Local Conventional‐Dose Hypofractionated Radiotherapy Enhances Antitumor and Immunomodulatory Effect

  2025cites this paper
• Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China

  2025cites this paper
• HHLA3 Silencing Suppresses KRAS‐Mutant Non‐Small‐Cell Lung Cancer Cell Progression Through Triggering MYEOV‐Mediated Ferroptosis

  2025cites this paper
• Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer

  2025cites this paper
• Vitamin D Deficiency in Smokers: A Major Risk Factor in Lung Carcinogenesis

  2025cites this paper
• Auranofin resensitizes ferroptosis-resistant lung cancer cells to ferroptosis inducers.

  2025cites this paper
• DRP2 promotes EMT and serves as a potential therapeutic target for LUAD treatment

  2025cites this paper
• FLAIR-based radiomics signature from brain-tumor interface for early prediction of response to EGFR-TKI therapy in NSCLC patients with brain metastasis

  2025cites this paper
• Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers.

  2025cites this paper